August 31st, 2010
Positive Results for Rivaroxaban in EINSTEIN-DVT
Larry Husten, PHD
The EINSTEIN-DVT study tested the effect of the new oral anticoagulant rivaroxaban in the setting of DVT. The open-label, non-inferiority study randomized more than 3,400 patients with acute, symptomatic DVT to either oral rivaroxaban or conventional therapy with enoxaparin followed by warfarin or acenocoumarol for 3, 6, or 12 months, based on the attending physician’s […]
NEJM Journal Watch — Recent Cardiology Articles- Estimating Heart Failure Risk in the U.S. Population with the PREVENT Calculator
- Atrial Fibrillation and Stable Coronary Artery Disease — What Is the Optimal Anticoagulation–Antiplatelet Regimen?
- β-Blockers After Myocardial Infarction
- Updated Guideline for Perioperative Cardiovascular Management of Patients Undergoing Noncardiac Surgery
- Strategies and Criteria for the Diagnosis and Management of Myocarditis